agtc appoints david r guyer md and ivana magovcevicliebisch phd jd to its board of directors nasdaqagtc facebook google linkedin twitter email rss jun   « previous release  next release » pdf agtc appoints david r guyer md and ivana magovcevicliebisch phd jd to its board of directors gainesville fla june   globe newswire  applied genetic technologies corporation nasdaqagtc a clinical stage biotechnology company developing adenoassociated virus aavbased gene therapies for the treatment of rare eye diseases today announced that it has appointed david r guyer md and ivana magovcevicliebisch phd jd to the companys board of directors dr guyer and dr magovcevicliebisch bring important expertise and industry leadership to the agtc board of directors and i expect that both will be instrumental to our success in realizing the potential of our bestinclass technology and product portfolio said dr scott koenig md chairman of the agtc board of directors we believe that the combination of davids significant track record in developing and commercializing ophthalmologic therapies with ivanas extensive experience in biopharmaceutical business development and operations will prove a powerful asset for agtc as we advance our genebased product candidates for genetic eye diseases i am pleased to welcome them to the agtc board of directors dr guyer is cofounder chief executive officer and chairman of the board of ophthotech corporation under his leadership ophthotech has successfully completed several rounds of private and public financing and entered into an exus licensing and commercialization deal for fovista® with novartis that is one of the largest exus partnering transactions in the biotechnology industry previously dr guyer cofounded and served as ceo and director at eyetech pharmaceuticals inc where he oversaw the rapid development and successful commercialization of macugen® pegaptanib sodium the first fdaapproved antivegf pharmacological treatment for wet amd dr guyer also was a venture capitalist and partner at sv life sciences and has served on multiple boards of both public and private companies dr guyer received his bs from yale college summa cum laude and his md from the johns hopkins university school of medicine he completed his ophthalmology residency at the wilmer ophthalmological institute at johns hopkins hospital and a retinal fellowship at the massachusetts eye and ear infirmary at harvard medical school agtcs proprietary aav platform has tremendous potential to address substantial unmet medical need i welcome the opportunity to join agtcs board of directors and look forward to working with the companys leadership to realize the full potential of the aav platform and to improve the care and outcomes for patients noted dr guyer as senior vice president head of global business development for teva pharmaceutical industries ltd since april  dr magovcevicliebisch is responsible for the execution of transactions identified by tevas rd global franchises and us specialty teams including the licensing andor acquisition of commercial products drug candidates and technologies prior to teva dr magovcevicliebisch served as an executive officer of dyax corp during her twelveyear tenure she held several senior positions within the company most recently serving as executive vice president and chief operating officer at dyax she oversaw successful commercialization of kalbiter® ecalantide the first subcutaneous treatment approved in the us for treatment of acute attacks of hereditary angioedema a life threatening orphan disease dr magovcevicliebisch was also instrumental in establishing dyaxs licensing and funded research programs lfrp based on its proprietary phase display technology which has been successfully licensed to over  licenses and collaborators and has generated numerous clinical stage candidates and two approved products prior to dyax dr magovcevicliebisch was director of intellectual property and patent counsel for transkaryotic therapies inc cambridge ma she received her jd from suffolk university law school and her phd in genetics from harvard university agtc has developed a novel and proprietary aav manufacturing system that can be broadly applied to developing innovative therapies for genetic eye diseases as well as many conditions that result from single gene mutations said dr magovcevicliebisch  i am pleased to have the opportunity to collaborate with my fellow directors to ensure that agtc leverages its products processes and platforms to create value for both agtcs shareholders and patients the company also announced that two current members of its board of directors jill carroll a class ii director and dr sam wu a class i director have notified the board of their intentions to rotate off the board at the companys next board meeting which will take place in july consistent with policies of the venture investment firms with which they are affiliated we thank jill and sam for their valuable service to agtc said dr koenig and we look forward to their continued contributions and counsel during their remaining tenure as directorsabout agtc agtc is a clinicalstage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe inherited orphan diseases in ophthalmology agtcs lead product candidates which are each in the preclinical stage focus on xlinked retinoschisis achromatopsia and xlinked retinitis pigmentosa which are rare diseases of the eye caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments for additional information visit wwwagtccomforward looking statements statements in this press release should be read in conjunction with the companys registration statement on form s file no  as amended filed with the sec in addition to historical financial information the following discussion contains forwardlooking statements that reflect the companys plans estimates assumptions and beliefs actual results could differ materially from those discussed in the forwardlooking statements forwardlooking statements include information concerning possible or assumed future results of operations business strategies and operations preclinical and clinical product development and regulatory progress financing plans potential growth opportunities potential market opportunities and the effects of competition forwardlooking statements include all statements that are not historical facts and can be identified by terms such as anticipates believes could seeks estimates expects intends may plans potential predicts projects should will would or similar expressions and the negatives of those terms given these uncertainties you should not place undue reliance on these forwardlooking statements also forwardlooking statements represent managements plans estimates assumptions and beliefs only as of the date of this release except as required by law we assume no obligation to update these forwardlooking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forwardlooking statements even if new information becomes available in the futurecontact david carey lazar partners ltd t   dcareylazarpartnerscom corporate contact larry bullock chief financial officer applied genetic technologies corporation t   lbullockagtccom david r guyer md executive profile  biography  bloomberg july    am et biotechnology company overview of ophthotech corporation snapshotpeople  overviewboard memberscommittees executive profile david r guyer mdcofounder  executive chairman ophthotech corporationagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationshipsas of fiscal year  background dr david r guyer md has been an advisor of sound pharmaceuticals inc since april   dr guyer is a consultant on ophthalmic products to more than  different pharmaceutical companies he has been the executive chairman at ophthotech corporation since july   and has been its executive director since january  he is a cofounder and executive chairman of imagen biotech inc he cofounded ophthotech corporation and served as its chief executive  officer from april  to july   he served as scientific advisor of iconic therapeutics inc he was a venture partner of sv health investors llc which he joined in may  he was a partner at sv health investors llc and is focused on biotechnology he cofounded eyetech pharmaceuticals inc and served as its chief executive officer dr guyer was a cofounder of oldtech inc and served as its chief executive officer since february  he served as a consultant to management and the board at osi pharmaceuticals where he provides specialist input in ophthalmology and retinal disease he served as chief executive officer osi eyetech at osi pharmaceuticals inc from november  to may  he served as an executive vice president at osi pharmaceuticals inc from november   to may  he serves as the chairman of panoptica inc he served as chairman of ophthotech corporation since january  until july   he served as chairman at new york university college of medicine he served as the chairman of danube pharmaceuticals inc since june  he has been a nonexecutive director of thrombogenics nv since december   and applied genetic technologies corporation since june   he serves on the boards of imagen biotech inc he served as director of allocure inc eyetech pharmaceuticals inc and neurotech pharmaceuticals inc he served as the chairman of lux biosciences inc dr guyer served as director of link medicine corporation and neovista inc he served as a nonexecutive director of optos plc from may   to april   he served as a director at eyetech he served as director of oldtech inc since february  he served as director of lux biosciences inc since july  he served as director of danube pharmaceuticals inc since june  he served as the chairman of nyu elaine a and kenneth g langone medical center he was the study cochairman of the pharmacological therapy for macular degeneration study group dr guyer served as a professor and chairman of the ophthalmology department at the new york university school of medicine he was professor and chairman of the department of ophthalmology at the nyu school of medicine he is an author of more than  publications he is an internationally recognized authority on macular diseases particularly the use of antiangiogenic drugs for the treatment of amd and diabetic macular edema dme he was ophthalmology resident at the wilmer eye institute at johns hopkins hospital and did his fellowship training in retinal surgery at the massachusetts eye and ear infirmary where he was a heedknapp fellow he completed his ophthalmology residency at the wilmer ophthalmological institute at johns hopkins hospital and a retinal fellowship at the massachusetts eye and ear infirmary at harvard medical school dr guyer received an md from the johns hopkins university school of medicine and a bsc degree from yale collegeread full background corporate headquarters one penn plazanew york new york united statesphone fax  board members memberships directorlink medicine corporationchairmanpanoptica incexecutive chairman and cofounderimagen biotech incpresentcofounder  executive chairmanophthotech corporationpresentnonexecutive directorthrombogenics nvpresentdirectorapplied genetic technologies corporation education md johns hopkins universitybs yale college other affiliations optos plcneurotech pharmaceuticals incosi pharmaceuticals incthrombogenics nvoldtech incsv health investors llcjohns hopkins universityyale collegeapplied genetic technologies corporationnyu elaine a and kenneth g langone medical centerneovista incsound pharmaceuticals inclux biosciences incdanube pharmaceuticals inclink medicine corporationnew york university college of medicineallocure inciconic therapeutics incpanoptica incimagen biotech inc annual compensation salarytotal annual compensation stocks options restricted stock awardsall other compensationexercised optionsexercised options valueexercisable optionsunexercisable optionstotal value of optionstotal number of options total compensation total annual cash compensationtotal short term compensationother long term compensationtotal calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact ophthotech corporation please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close david r guyer is no longer serving in their position at ophthotech corp news home advertising board and executive moves energy health care hedge funds m  a private equity technology see more news on board and executive moves in health care david r guyer is no longer serving in their position at ophthotech corp email linkedin facebook google tweet reddit permalink jul    relsci data update board and executive moves background information david r guyer » cofounder at imagen biotech inc career imagen biotech inc sv life sciences advisers llp sv health investors boards applied genetic technologies corp thrombogenics nv imagen biotech inc education john hopkins university  school of medicine yale university  yale college the johns hopkins university in the news ophthotech reports first quarter  financial and operating results may    •  business wire david r guyer sold m worth of shares in ophthotech corp in september  october    •  relsci david r guyer sold m worth of shares in ophthotech corp in august  september    •  relsci david r guyer » cofounder at imagen biotech inc career • imagen biotech inc • sv life sciences advisers llp • sv health investors boards • applied genetic technologies corp • thrombogenics nv • imagen biotech inc education • john hopkins university  school of medicine • yale university  yale college • the johns hopkins university in the news ophthotech reports first quarter  financial and operating results  may    •  business wire david r guyer sold m worth of shares in ophthotech corp in september   october    •  relsci david r guyer sold m worth of shares in ophthotech corp in august   september    •  relsci ophthotech corp » ophthotech corp operates as a biopharmaceutical company it focuses on discovering developing and commercializing novel therapeutics to treat diseases of the back of the eye it develops therapies for agerelated macular degeneration its product candidates include fovista anti platelet derived growth factor therapy zimura anticomplement and aptamer technology the company was founded by david r guyer and samir chandrakant patel on january   and is headquartered in new york ny in the news ophthotech corporation to report first quarter  financial results and host conference call on wednesday may   april    •  business wire ophthotech  hour deadline alert approximately  hours remain former louisiana attorney general and kahn swick  foti llc remind investors of deadline in class action lawsuit against ophthotech corporation  opht march    •  business wire investor complaint levi  korsinsky llp reminds investors of ophthotech corporation of a class action lawsuit and a lead plaintiff deadline of march   march    •  legal monitor worldwide ophthotech corp » ophthotech corp operates as a biopharmaceutical company it focuses on discovering developing and commercializing novel therapeutics to treat diseases of the back of the eye it develops therapies for agerelated macular degeneration its product candidates include fovista anti platelet derived growth factor therapy zimura anticomplement and aptamer technology the company was founded by david r guyer and samir chandrakant patel on january   and is headquartered in new york ny in the news ophthotech corporation to report first quarter  financial results and host conference call on wednesday may    april    •  business wire ophthotech  hour deadline alert approximately  hours remain former louisiana attorney general and kahn swick  foti llc remind investors of deadline in class action lawsuit against ophthotech corporation  opht  march    •  business wire investor complaint levi  korsinsky llp reminds investors of ophthotech corporation of a class action lawsuit and a lead plaintiff deadline of march    march    •  legal monitor worldwide see more news on board and executive moves in health care youve found a premium relsci pro feature connect to individuals and organizations in this story upgrade to relsci pro to easily sync your contacts and see how you can reach the people and organizations featured in this article start my free trial ➤ still not convinced check out our full listing of features here not now are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ agtc appoints david r guyer md and ivana magovcevicliebisch phd jd to its board of directors  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street agtc appoints david r guyer md and ivana magovcevicliebisch phd jd to its board of directors globenewswire jun    am edt gainesville fla june   globe newswire  applied genetic technologies corporation nasdaqagtc a clinical stage biotechnology company developing adenoassociated virus aavbased gene therapies for the treatment of rare eye diseases today announced that it has appointed david r guyer md and ivana magovcevicliebisch phd jd to the companys board of directors dr guyer and dr magovcevicliebisch bring important expertise and industry leadership to the agtc board of directors and i expect that both will be instrumental to our success in realizing the potential of our bestinclass technology and product portfolio said dr scott koenig md chairman of the agtc board of directors we believe that the combination of davids significant track record in developing and commercializing ophthalmologic therapies with ivanas extensive experience in biopharmaceutical business development and operations will prove a powerful asset for agtc as we advance our genebased product candidates for genetic eye diseases i am pleased to welcome them to the agtc board of directors dr guyer is cofounder chief executive officer and chairman of the board of ophthotech corporation under his leadership ophthotech has successfully completed several rounds of private and public financing and entered into an exus licensing and commercialization deal for fovista ® with novartis that is one of the largest exus partnering transactions in the biotechnology industry previously dr guyer cofounded and served as ceo and director at eyetech pharmaceuticals inc where he oversaw the rapid development and successful commercialization of macugen® pegaptanib sodium the first fdaapproved antivegf pharmacological treatment for wet amd dr guyer also was a venture capitalist and partner at sv life sciences and has served on multiple boards of both public and private companies dr guyer received his bs from yale college summa cum laude and his md from the johns hopkins university school of medicine he completed his ophthalmology residency at the wilmer ophthalmological institute at johns hopkins hospital and a retinal fellowship at the massachusetts eye and ear infirmary at harvard medical school agtcs proprietary aav platform has tremendous potential to address substantial unmet medical need i welcome the opportunity to join agtcs board of directors and look forward to working with the companys leadership to realize the full potential of the aav platform and to improve the care and outcomes for patients noted dr guyer trending amazon deceptive pricing probe by the ftc could be the start of a government siege sears just surrendered to amazon with kenmore deal dont sleep on general electrics cheap stock price chipotles new health scare could trigger a hindenburg scenario expert says bored with cream and sugar you can now add weed to your morning joe advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers nothing found for management david r guyer m d ophthotech  error page home  ›   error our apologies youve somehow landed on a page that doesnt exist the retina atlas  david r guyer   home contact us help free delivery worldwide order status wishlist sign injoin  search advanced search free delivery worldwide free delivery worldwide shop by category categories childrens age ranges all categories browse all art  photography audio books biography business finance  law childrens books computing crafts  hobbies crime  thriller dictionaries  languages entertainment fiction food  drink graphic novels anime  manga health history  archaeology home  garden humour medical mind body  spirit natural history personal development poetry  drama reference religion romance science  geography science fiction fantasy  horror society  social sciences sport stationery teaching resources  education technology  engineering teen  young adult transport travel  holiday guides childrens books by age range ages  ages  ages  ages  teen  young adult top authors j k rowling roald dahl julia donaldson stephen king david walliams dr seuss andy griffiths james patterson sarah j maas enid blyton john green brandon sanderson see all bestselling series harry potter game of thrones lego divergent throne of glass star wars popular features books and movies gift guides book club classics best books ever adult colouring books bestsellers coming soon highlights bargain shop  australian dollar € euro  us dollar £ british pound  new zealand dollar  singapore dollar  hong kong dollar  canadian dollar kč czech koruna ₪ israeli shekel ￥ japanese yen kr norwegian krone zł polish zloty kr swedish krona chf swiss franc ฿ thai baht kr danish krone ft hungarian forint  taiwan new dollar r south african rand  mexican peso  argentine peso  chilean peso rm malaysian ringgit ￦ south korean won rp indonesian rupiah us  items categories ophthalmology the retina atlas hardback english by author  david r guyer  by author  w richard green  by author  lawrence a yannuzzi share list price us currently unavailable add to wishlist abebooks may have this title opens in new window try abebooks description this atlas serves as a fourth volume and color component to ryans retina e to illustrate the various medicalretinal disorders and their pathologies the combination of c clinical photography fluorescein angiography and c histopathological pictures supported by black white schematics contributes to a thorough illustration of the retinal disease process in particular the histopathology will serve to explain the genesis of the various retinal diseases found in the clinical photographs this atlas is the first to publish indocyanine green angiography icg findings a technique developed by guyer and yannuzzi for diagnosing and treating macular degeneration  the leading cause of blindness in the western world this information is presented in the ryan second edition text and will be of great interest to general ophthalmologists in their initial evaluation and screening of patients the scope and depth of this book as it is keyed to ryans retina e will allow the resident clinical ophthalmologist retinal specialist and research specialist to use is as their complete diagnosticresearch toolshow more product details format hardback   pages dimensions  x  x mm  g publication date  jan  publisher elsevier health sciences imprint mosby publication citycountry london united kingdom language english illustrations note  illus isbn  isbn  bestsellers in ophthalmology iridology simplified bernard jensen  oct  paperback us  us save us add to basket off ophthobook timothy root  jul  paperback us  us save us add to basket root eye dictionary timothy root md  aug  paperback us add to basket off macular degeneration lylas g mogk  aug  paperback us  us save us add to basket off the wills eye manual nika bagheri  jun  paperback us  us save us add to basket off oxford handbook of ophthalmology alastair denniston  dec  partwork fascículo us  us save us add to basket off moorfields manual of ophthalmology timothy l jackson  oct  paperback us  us save us add to basket off adlers physiology of the eye leonard a levin  may  hardback us  us save us add to basket everyday oct joel s schuman  feb  spiral bound us  us save us add to basket vitreoretinal surgery  ferenc kuhn  nov  hardback us add to basket off retina  vitreous surgery subhendu kumar boral  feb  hardback us  us save us add to basket off lecture notes ophthalmology bruce james  dec  paperback us  us save us add to basket off clinical optics andrew r elkington  oct  paperback us  us save us add to basket off clinical anatomy of the eye e richard s snell  jan  paperback us  us save us add to basket off the art of cosmic vision mantak chia  apr  paperback us  us save us add to basket off kanskis clinical ophthalmology brad bowling  jun  hardback us  us save us add to basket off common neuroophthalmic pitfalls valerie a purvin  feb  paperback us  us save us add to basket off clinical management of binocular vision mitchell scheiman  aug  paperback us  us save us add to basket the story of my eyes ellis barker  jun  paperback us add to basket opthalmic diseases  their homoeopathic therapeutics ab norton  jan  hardback unavailable notify me off visual perception problems in children with adhd autism and other learning disabilities lisa a kurtz  may  paperback us  us save us add to basket off the unofficial guide to passing osces zeshan qureshi  feb  paperback us  us save us add to basket off dry eye remedy the revised edition robert latkany  apr  paperback us  us save us add to basket off review of ophthalmology neil j friedman  mar  paperback us  us save us add to basket off geometrical and visual optics steven h schwartz  jul  hardback us  us save us add to basket vision therapy dean liguori  may  paperback us add to basket off diagnosis and management of ocular motility disorders alec m ansons  jan  hardback us  us save us add to basket the neuroophthalmology survival guide anthony pane  may  paperback us add to basket off shared care glaucoma amar alwitry  jun  paperback us  us save us add to basket healing is voltage md jerry l tennant md  jun  paperback us add to basket eye movement desensitization and reprocessing emdr scripted protocols marilyn luber  may  paperback us  us save us add to basket off ophthalmic nursing mary e shaw  jul  paperback us  us save us add to basket off last minute optics david g hunter  apr  paperback us  us save us add to basket off training in ophthalmology venki sundaram  sep  paperback us  us save us add to basket off emergencies of the orbit and adnexa  bipasha mukerjee  jan  hardback us  us save us add to basket off ophthalmology gerhard klaus lang  dec  paperback us  us save us add to basket fast facts glaucoma paul r healey  mar  paperback us  us save us add to basket off vision for life revised edition meir schneider  may  paperback us  us save us add to basket off read again without glasses leo angart  sep  mixed media product us  us save us add to basket off handbook of retinal oct optical coherence tomography jay s duker  jan  paperback us  us save us add to basket off injectable fillers in aesthetic medicine mauricio de maio  apr  hardback us  us save us add to basket color psychology and color therapy faber birren  nov  paperback us add to basket off frcophth  sbas and crqs part  nikki hall  mar  paperback us  us save us add to basket off cornea volume set mark j mannis  nov  hardback us  us save us add to basket off slatters fundamentals of veterinary ophthalmology david maggs  feb  hardback us  us save us add to basket off eye pathology ralph c eagle  dec  hardback us  us save us add to basket off test yourself atlas in ophthalmology jack j kanski  aug  paperback us  us save us add to basket eye movement disorders agnes wong  jun  paperback us add to basket optics and optical instruments b k johnson  nov  paperback us  us save us add to basket off case reviews in ophthalmology neil j friedman  may  paperback us  us save us add to basket categories ophthalmology follow us agtc appoints david r guyer md and ivana magovcevicliebisch phd jd to its board of directors  pg  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street agtc appoints david r guyer md and ivana magovcevicliebisch phd jd to its board of directors globenewswire jun    am edt we thank jill and sam for their valuable service to agtc said dr koenig and we look forward to their continued contributions and counsel during their remaining tenure as directors about agtc agtc is a clinicalstage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe inherited orphan diseases in ophthalmology agtcs lead product candidates which are each in the preclinical stage focus on xlinked retinoschisis achromatopsia and xlinked retinitis pigmentosa which are rare diseases of the eye caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments for additional information visit wwwagtccom forward looking statements statements in this press release should be read in conjunction with the companys registration statement on form s file no  as amended filed with the sec in addition to historical financial information the following discussion contains forwardlooking statements that reflect the companys plans estimates assumptions and beliefs actual results could differ materially from those discussed in the forwardlooking statements forwardlooking statements include information concerning possible or assumed future results of operations business strategies and operations preclinical and clinical product development and regulatory progress financing plans potential growth opportunities potential market opportunities and the effects of competition forwardlooking statements include all statements that are not historical facts and can be identified by terms such as anticipates believes could seeks estimates expects intends may plans potential predicts projects should will would or similar expressions and the negatives of those terms given these uncertainties you should not place undue reliance on these forwardlooking statements also forwardlooking statements represent managements plans estimates assumptions and beliefs only as of the date of this release except as required by law we assume no obligation to update these forwardlooking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forwardlooking statements even if new information becomes available in the future contact david carey lazar partners ltd t   dcareylazarpartnerscom corporate contact larry bullock chief financial officer applied genetic technologies corporation t   lbullockagtccom trending amazon deceptive pricing probe by the ftc could be the start of a government siege sears just surrendered to amazon with kenmore deal dont sleep on general electrics cheap stock price chipotles new health scare could trigger a hindenburg scenario expert says bored with cream and sugar you can now add weed to your morning joe advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers david guyer pmp  linkedin linkedin main content starts below david guyer pmpproject manager at bosch north americalocationgreater detroit areaindustryautomotivepreviousvocollect sony ericsson motorolaeducationflorida international university  college of business administrationrecommendations people have recommended david connectionsview david’s full profile its freeyour colleagues classmates and  million other professionals are on linkedinview david’s full profilesummary♦ davidguyeryahoocom  ☎  pmi certified program manager with an mba bringing  years’ experience and skills in matrix managing diverse crossfunctional teams through complete manufacturing product development lifecycle creating and managing project schedules and budgets problem solving customer interface and global team building that maximizes value for both the organization and customeras a program manager i love to solve problems—starting with what the customer needs and continuing through technical and logistic issues if i am leading a problem resolution effort i am not only doing what comes naturally to me i am also doing what i most enjoy i effectively use my engineering background to assist in successful program management through risk analysis project schedule and budget estimation and problem resolution i believe every decision made in a project should consider the broader business impacts and continually stress this approach to project teamsintegrated hardware and software engineering verification marketing supply chain and production teams in the development and customer introduction of multiple subscriber devices for cellular and industrial applications specialties proven track record of product development and manufacturing in asia  risk management and mitigation  cross functional team buildingexperiencesenior project managervocollectjuly  – november   years  monthsmanaged a cross functional product development team for next generation wearable computer hardware platform for complete product life cycleproduct owner for hardware device in agilescrum embedded software development process that brought effective change management to early prototype stage resolving requests within upcoming sprint and managed further development and launch drove cost of goods for wearable industrial computer product to  of target at introductiondevelopment program managersony ericssonoctober  – june   years  monthsmanaged global hardware platform team of up to  diverse staff members in on time  on budget prototype delivery of sony ericsson gaming cell phone platform utilizing asian manufacturingrd project manager of cross functional handset development teams for cellular products including asian manufacturing projects included both windows mobile and android platformsled mobile computing development team’s introduction of two usb modem projects from development through product launch and volume production phasesprincipal program managermotorolajune  –   yearsachieved customer acceptance at senior vp level of new voice coder overcoming technical challenges with creative compromise solutions that helped major cellular operator control capital expenditures while growing subscriber basesupervised a cross functional team of up to  diverse staff members in a matrix organization obtaining customer acceptance of a new cell phone platform  weeks ahead of schedule contributing an additional  margin contribution above the business plan by identifying expedite opportunities with high paybackprojectsmotorola iden cdma phone launched in september  – september my responsiblity include  customer contact window and manage customer requirement leader for global program team and drive design team rd team npi sourcing manufacuring team working together to delivery productteam members david guyer pmp ashley wang ma xiang jim conroy pmp victor meng peng saihuangcoursesindependent courseworkagile prep castagile prep castvolunteer experience  causesconstruction volunteerhabitat for humanity international – present  yearseconomic empowermentparticipated in construction efforts both locally in the triangle and in central americacauses david cares aboutdisaster and humanitarian reliefcertificationspmppmi license july  – july skillsproduct developmentcellularwirelessmanufacturingprogram managementmobilepmpwificellular communicationsmobile devicesbluetoothrfcrossfunctional team leadershipembedded softwareproduct lifecycle managementsee software engineeringpcb designmobile communicationsandroidsystem architecturetestingelectronicsproduct managementtelecommunicationsgembedded systemsltemobile technologydebuggingengineering managementcdmaintegrationrtosgotomarket strategyarmfirmwaregsmproject managementclearcasecrmsystems engineeringagile project managementsoftware developmentmobile applicationsumtshardwaresoftware project managementagile methodologiesdevice driversgppsee lesshows this translationgreat•has errorsthanks for your helpeducationflorida international university  college of business administrationmba business administration and management generalmba business administration and management generalpenn state universitybsee electrical engineeringbsee electrical engineeringrecommendationsa preview of what linkedin members have to say about davidi have known david guyer as a project manager at sony ericsson for over a year where we worked together on the md product david on hardware myself as software project manager david managed a complex project under an extremely tight schedule coordinating designers materials industrialization and manufacturing we were able to meet early delivery goals for sales and field test and delivery the final product on time ive always found david to be a thorough and intense thinker and i know the projects success was due to his active involvement in summary i highly recommend david he will be a valuable asset for any organization if you have any questions please do not hesitate to contact me sincerely peter pagliasee moresee lessi worked with david on a mobile device software projects at motorola in his role as a program manager in that project we have many third parties davids broad knowledge of mobile product development from hardware software and factory preparation to scheduling skills and communication abilities ensure the project has a good base as quick as possible david is a great team builder so that our project team was created well quickly although many teams are overseas i am glad working with davidsee moresee lesssign up to see who recommended davidgroupsthe project manager network   group for project managersproject and portfolio management with microsoft projectexmotorolanspmo experienced practicing project and program managersmobile productsthe penn state alumni associationlinkmeinsee  moreericsson  sony ericsson  rtpstagegate userslinking the triangleself driving carssee lessview david’s full profile tosee who you know in commonget introducedcontact david directlyview david’s full profileview this profile in another languageenglishchinese simplifiedgermanpeople also viewedrebekah sharrst in emergency medicinepierre lefaixtechnical project manager at bosch north americadave baumleinpharmacist at buehler pharmacyjon jamesbosch at boschhesham odat phdprogram manager at robert boschsam beydounproject management at robert boschmark kingdirector at boschsteve zukowskiproduct manager at robert bosch llcmax huqsr account manager at robert bosch llcandrew keverenoch kever pllc managing memberpublic profile badgeinclude this linkedin profile on other websitesview profile badgessearch by nameover  million professionals are already on linkedin find who you knowfirst namelast nameexample jeff weinerlinkedin member directoryabcdefghijklmnopqrstuvwxyzmorebrowse members by country david r guyer    scenic heights dr elgin ia  nuwber  david r guyer age — phone    is a mobile number address  scenic heights dr elgin ia  relatives  associated lindsey l guyer see more results for david guyer in iowa  see more results for guyer in elgin ia  in iowa   scenic heights dr elgin ia home type single family dwelling unit build year  show map direction street view aerial view birds eye × route × streetview × aerial view × birds eye neighbors for david guyer james d knobloch  scenic heights dr caleb j knobloch  scenic heights dr marcy d knobloch  scenic heights dr kenneth sindergard  scenic heights dr sara a strong  scenic heights dr duane a strong  scenic heights dr ron soppe  scenic heights dr renessa d zurbriggen  scenic heights dr l l wedo  scenic heights dr andrew e dirksen  scenic heights dr julianna ziegler  scenic heights dr sharla s frank  scenic heights dr aaron j frank  scenic heights dr alan h seabrooke  scenic heights dr kari m seabrooke  scenic heights dr see all neighbors on the scenic heights dr elgin ia probably you are looking for david k guyer age – • bettendorf ia microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft background checks and public records search  truthfinder call toll free   public records search social media photos police records background checks contact information and much more start here  try searching a friend relative celebrity yourself or someone else you might know first name last name city state all states alabama alaska arizona arkansas california colorado connecticut district of columbia delaware florida georgia hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota ohio oklahoma oregon pennsylvania rhode island south carolina south dakota tennessee texas utah vermont virgin islands virginia washington west virginia wisconsin wyoming this is me searching for yourself search this secure connection is confirmed were very popular what our happy users are saying truthfindercom is freakishly accurate… really scary how much info is out there zac k you found an old friend for me thank you nancy v truthfinder is an excellent site for finding out about someone sherrie f this site is so wonderful i found my lost godchildren and their mom thank you so much lawrence w this is one way to really know a potential date charmaine r your service is more than perfect it is a blessing thank you for the very hard work that you do richard b truthfinder is a very accurate updated system their information is proper and can be very helpful too juan m notice this site contains real police records court records of driving citations speeding tickets felonies misdemeanors sexual offenses mugshots etc background reports photos court documents address information phone numbers and much more please be careful when conducting a search and ensure all the information you enter is accurate learning the truth about the history of your family and friends can be shocking so please be cautious when using this tool truthfinder does not provide consumer reports and is not a consumer reporting agency we provide a lot of sensitive information that can be used to satisfy your curiosity protect your family and find the truth about the people in your life you may not use our service or the information it provides to make decisions about consumer credit employers insurance tenant screening or any other purposes that would require fcra compliance i understand help us refine your results select your gender male female next skip